Judge et al. observed a significant up-regulation of the level of CD69, an activation marker for NK cells, in tumor-infiltrating lymphocytes treated with IL-15, effectively treating soft tissue sarcoma (STS) [164]. Here, IL15 is linked to neoplasm.